Scleroderma, Diffuse
6 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Scleroderma, Systemic
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belimumab for scleroderma, diffuse | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MTX-474 for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| QEL-005 for scleroderma, diffuse | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telitacicept for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tulisokibart for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.